A Phase 3 interventional study of adalimumab in Ankylosing Spondylitis, sponsored by Abbott. Completed at 19 sites in Japan. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2012-01-26.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing adalimumab in Spondylitis, Ankylosing — 2 open to participants now, 3 under way, none of them phase 3. Adalimumab · Spondylitis, Ankylosing.
Among the 19 studies testing adalimumab in Spondylitis, Ankylosing, this one is the 16th largest by enrollment, is one of 2 that started in 2008, is one of 7 in phase 3, and was the 5th registered.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 98 are open to participants now.
Browse Spondylitis, Ankylosing studies →2 of the 19 studies testing adalimumab in Spondylitis, Ankylosing are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
The Affiliated Hospital Of Guizhou Medical University · Sites in China
Ages 18+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 62 Spondylitis, Ankylosing studies recruiting now, 24 (39%) set no upper age limit and 32 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 15 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 8 · Phase 4 8
First in 2003; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 80 across the 19 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 19 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
Abbott has 7 studies filed under Spondylitis, Ankylosing — fewer than ten, so there is no comparison to draw.
1 of the studies testing adalimumab in Spondylitis, Ankylosing that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06833112The Affiliated Hospital Of Guizhou Medical UniversityInterleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing adalimumab in Spondylitis, Ankylosing, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with active ankylosing spondylitis
It is reported that the prevalence of Ankylosing Spondylitis (AS) in Japanese patients is extremely lower than that of Caucasians; therefore, a controlled, double-blind study with similar sample size in Western studies for active AS in Japan was not able to be conducted. As a result, this study was conducted with an open-label design to investigate efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with active AS. The inclusion criteria and primary endpoint measurement (Achieving Assessment in Ankylosing Spondylitis 20 at Week 12) were designed the same as the Western studies for active AS in consideration with the confirmation of Western data. Treatment with adalimumab was to be continued until the approval of adalimumab for AS in Japanese subjects with active AS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adalimumab 40 mg or 80 mg subcutaneously (SC) administered every other week (eow) until approval of adalimumab for Ankylosing Spondylitis (AS) in Japan. All subjects received 40 mg of adalimumab SC eow at Baseline. The subjects who completed 16 weeks of therapy and who failed to achieve Assessments in Ankylosing Spondylitis 20 (ASAS 20) response on or after Week 16, could increase the dose of adalimumab to 80 mg eow. When the dose was increased, the higher dose was to be continued during the rest of the study.
Biological: adalimumab
40 mg or 80 mg every other week, subcutaneous
Also known as: ABT-D2E7, Humira
Number of Subjects Achieving Assessment in Ankylosing Spondylitis 20 (ASAS 20) at Week 12
ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 20 = at least 20% improvement (vs. baseline) and an absolute improvement ≥ 10 units on a 0 - 100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.
Time frame: Week 12
Number of Subjects Achieving ASAS 20
ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 20 = 20% improvement (vs. baseline) and an absolute improvement ≥ 10 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.
Time frame: Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Number of Subjects Achieving ASAS 50
ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 50 = at least 50% improvement (vs. baseline) and an absolute improvement ≥ 20 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.
Time frame: Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Number of Subjects Achieving ASAS 70
ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 70 = at least 70% improvement (vs. baseline) and an absolute improvement ≥ 30 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.
Time frame: Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Number of Subjects Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI 50)
BASDAI is a validated self assessment tool used to determine disease activity in subjects with Ankylosing Spondylitis (AS). Utilizing a Visual Analog Scale (VAS) of 0-10 (0=none and 10=very severe) subjects answered 6 questions measuring discomfort, pain, fatigue, and morning stiffness. BASDAI 50 = at least 50% improvement (vs. baseline) in BASDAI.
Time frame: Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Mean Change From Baseline in Patient's Global Assessment of Disease Activity
Subject's assessment of disease activity using a Visual Analog Scale (VAS) of 0 - 100 mm (0 = none and 100 = severe).
Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Mean Change From Baseline in Total Back Pain
Subject assessed his/her back pain by using a Visual Analog Scale (VAS) of 0 - 100 mm (0 = no pain and 100 = most severe pain).
Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)
BASFI is a validated self assessment tool that determines the degree of functional limitation in AS subjects. Utilizing a VAS of 0-100 mm (0=easy, 100=impossible), subjects answered 10 questions assessing their ability in completing normal daily activities or physically demanding activities. The BASFI score is a mean score of the 10 questions.
Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Mean Change From Baseline in C-Reactive Protein (CRP)
CRP is a marker of inflammation and measured in mg/dL. A higher level is consistent with inflammation.
Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Number of Subjects Achieving Assessment in Ankylosing Spondylitis (ASAS) 5/6.
ASAS 5/6 consists of 6 domains: the 4 used in ASAS 20 (patient global assessment of disease activity, pain, function, inflammation) plus spinal mobility and an acute phase reactant, C Reactive Protein (CRP). Achieving ASAS 5/6 requires a 20% improvement compared to baseline in ≥ 5 domains (each domain measured on a 0 - 100 scale \[0 = no disease activity; 100 = high disease activity\]).
Time frame: Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Number of Subjects Achieving Assessment in Ankylosing Spondylitis 40 (ASAS 40)
ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS = 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 40 = at least 40% improvement (vs. baseline) and an absolute improvement ≥ 20 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening in remaining domain.
Time frame: Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Number of Subjects Achieving Assessment in Ankylosing Spondylitis Partial Remission
Partial remission is defined as a score of less than 20 units (on a scale of 0-100; 0=no disease activity and 100=high disease activity) in each of the 4 Assessments in Ankylosing Spondylitis (ASAS) domains: patient global assessment of disease activity, pain, function, and inflammation.
Time frame: Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Mean Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)
BASMI is an objective measure of spinal mobility. The BASMI score is composed of 5 measures: tragus to wall distance, lumbar flexion, cervical rotation, lumbar side flexion, and intermalleolar distance. Each measure was scored 0-2 (0=normal mobility/mild disease involvement, 1=moderate disease involvement, 2=severe disease involvement) to give a final total score ranging from 0 to 10. The higher the BASMI score, the more severe was the subject's limitation of movement due to their AS.
Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Mean Change From Baseline in Chest Expansion
Chest expansion is the difference in centimeters between full expiration and full inspiration, measured at the 4th inter-costal space. An increase in chest expansion represents improvement.
Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Mean Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
Assessment of enthesitis was performed in the following 7 domains: 1) 1st costochondral joint left and right, 2) 7th costochondral joint left and right, 3) posterior superior iliac spine left and right, 4) anterior superior iliac spine left and right, 5) iliac crest left and right, 6) 5th lumbar spinous process and 7) proximal insertion of Achilles tendon left and right. Each domain was graded for the presence (1) and absence (0) of tenderness yielding total MASES ranging from 0 (no tenderness) to 13 (worst possible score; severe tenderness).
Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Mean Change From Baseline in Nocturnal Pain
Nocturnal pain assessed by subjects using a Visual Analog Scale (VAS) of 0 - 100 mm (0 = no pain and 100 = worst possible pain).
Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Mean Change From Baseline in Swollen Joint Count for 44 Joints (SJC 44)
The number of swollen joints among 22 anatomical joints for both the right and left side of the body were assessed by a joint evaluator where the presence of a swollen joint was scored as 1 and absence as 0. The total SJC was derived by the sum of the scores for a range of SJC from 0 (best possible score; no swollen joints) to 44 (worse possible score; all joints swollen).
Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Mean Change From Baseline in Tender Joint Count for 46 Joints (TJC 46)
The number of tender or painful joints among 23 anatomical joints for both the right and left side of the body were assessed by a joint evaluator where the presence of a tender or painful joint was scored as 1 and absence as 0. The total TJC was derived by the sum of the scores for a range of TJC from 0 (best possible score; no tender or painful joints) to 46 (worst possible score; all joints tender or painful).
Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Mean Change From Baseline in 36-Item Short Form (SF-36) Questionnaire
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These are summarized in a physical component summary (PCS) and mental component summary (MCS) score. The score for a section is an average of the individual question scores, which are scaled 0-100 (0=lowest level of functioning; 100=highest level of functioning).
Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
| Milestone | Adalimumab |
|---|---|
| Started | 41 |
| Completed | 30 |
| Not completed | 11 |
| Withdrew: Adverse event | 5 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Other reason was not specified | 5 |
ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 20 = at least 20% improvement (vs. baseline) and an absolute improvement ≥ 10 units on a 0 - 100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.
| Subjects | Adalimumab |
|---|---|
| Non-responder imputation (NRI), N = 41 | 30 |
| Last Observation Carried Forward (LOCF), N = 41 | 30 |
| Observed Cases, N = 40 | 30 |
ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 20 = 20% improvement (vs. baseline) and an absolute improvement ≥ 10 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.
| Subjects | Adalimumab |
|---|---|
| Week 12 | 30 |
| Week 24 | 30 |
| Week 48 | 32 |
| Week 72 | 32 |
| Week 96 | 27 |
| Week 120 | 21 |
| Final Visit | 32 |
ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 50 = at least 50% improvement (vs. baseline) and an absolute improvement ≥ 20 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.
| Subjects | Adalimumab |
|---|---|
| Week 12 | 23 |
| Week 24 | 26 |
| Week 48 | 26 |
| Week 72 | 25 |
| Week 96 | 19 |
| Week 120 | 17 |
| Final Visit | 27 |
ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 70 = at least 70% improvement (vs. baseline) and an absolute improvement ≥ 30 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.
| Subjects | Adalimumab |
|---|---|
| Week 12 | 13 |
| Week 24 | 16 |
| Week 48 | 18 |
| Week 72 | 17 |
| Week 96 | 15 |
| Week 120 | 13 |
| Final Visit | 19 |
BASDAI is a validated self assessment tool used to determine disease activity in subjects with Ankylosing Spondylitis (AS). Utilizing a Visual Analog Scale (VAS) of 0-10 (0=none and 10=very severe) subjects answered 6 questions measuring discomfort, pain, fatigue, and morning stiffness. BASDAI 50 = at least 50% improvement (vs. baseline) in BASDAI.
| Subjects | Adalimumab |
|---|---|
| Week 12 | 27 |
| Week 24 | 26 |
| Week 48 | 25 |
| Week 72 | 28 |
| Week 96 | 22 |
| Week 120 | 18 |
| Final Visit | 29 |
Subject's assessment of disease activity using a Visual Analog Scale (VAS) of 0 - 100 mm (0 = none and 100 = severe).
| mm on scale | Adalimumab |
|---|---|
| Week 12 | -34.6 (-42.80 to -26.33) |
| Week 24 | -37.3 (-45.99 to -28.69) |
| Week 48 | -39.5 (-47.52 to -31.51) |
| Week 72 | -39.7 (-48.14 to -31.32) |
| Week 96 | -37.1 (-45.96 to -28.34) |
| Week 120 | -40.1 (-48.61 to -31.53) |
| Final Visit | -40.6 (-48.81 to -32.32) |
Subject assessed his/her back pain by using a Visual Analog Scale (VAS) of 0 - 100 mm (0 = no pain and 100 = most severe pain).
| mm on scale | Adalimumab |
|---|---|
| Week 12 | -35.6 (-43.68 to -27.59) |
| Week 24 | -37.0 (-45.05 to -28.85) |
| Week 48 | -38.6 (-46.68 to -30.53) |
| Week 72 | -39.3 (-47.53 to -31.01) |
| Week 96 | -36.4 (-44.33 to -28.40) |
| Week 120 | -39.2 (-46.98 to -31.36) |
| Final Visit | -40.2 (-47.80 to -32.64) |
BASFI is a validated self assessment tool that determines the degree of functional limitation in AS subjects. Utilizing a VAS of 0-100 mm (0=easy, 100=impossible), subjects answered 10 questions assessing their ability in completing normal daily activities or physically demanding activities. The BASFI score is a mean score of the 10 questions.
| mm on scale | Adalimumab |
|---|---|
| Week 12 | -19.4 (-24.49 to -14.34) |
| Week 24 | -20.5 (-25.84 to -15.08) |
| Week 48 | -21.9 (-28.39 to -15.51) |
| Week 72 | -22.2 (-29.44 to -14.89) |
| Week 96 | -22.1 (-28.72 to -15.54) |
| Week 120 | -21.8 (-28.07 to -15.51) |
| Final Visit | -21.6 (-27.65 to -15.49) |
CRP is a marker of inflammation and measured in mg/dL. A higher level is consistent with inflammation.
| mg/dL | Adalimumab |
|---|---|
| Week 12 | -1.2 (-1.60 to -0.83) |
| Week 24 | -1.3 (-1.76 to -0.89) |
| Week 48 | -1.4 (-1.78 to -0.95) |
| Week 72 | -1.3 (-1.74 to -0.83) |
| Week 96 | -1.4 (-1.84 to -0.94) |
| Week 120 | -1.3 (-1.76 to -0.76) |
| Final Visit | -1.2 (-1.67 to -0.64) |
ASAS 5/6 consists of 6 domains: the 4 used in ASAS 20 (patient global assessment of disease activity, pain, function, inflammation) plus spinal mobility and an acute phase reactant, C Reactive Protein (CRP). Achieving ASAS 5/6 requires a 20% improvement compared to baseline in ≥ 5 domains (each domain measured on a 0 - 100 scale \[0 = no disease activity; 100 = high disease activity\]).
| Subjects | Adalimumab |
|---|---|
| Week 12 | 28 |
| Week 24 | 29 |
| Week 48 | 31 |
| Week 72 | 28 |
| Week 96 | 25 |
| Week 120 | 20 |
| Final Visit | 29 |
ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS = 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 40 = at least 40% improvement (vs. baseline) and an absolute improvement ≥ 20 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening in remaining domain.
| Subjects | Adalimumab |
|---|---|
| Week 12 | 26 |
| Week 24 | 26 |
| Week 48 | 27 |
| Week 72 | 28 |
| Week 96 | 24 |
| Week 120 | 18 |
| Final Visit | 26 |
Partial remission is defined as a score of less than 20 units (on a scale of 0-100; 0=no disease activity and 100=high disease activity) in each of the 4 Assessments in Ankylosing Spondylitis (ASAS) domains: patient global assessment of disease activity, pain, function, and inflammation.
| Subjects | Adalimumab |
|---|---|
| Week 12 | 15 |
| Week 24 | 16 |
| Week 48 | 17 |
| Week 72 | 20 |
| Week 96 | 15 |
| Week 120 | 13 |
| Final Visit | 19 |
BASMI is an objective measure of spinal mobility. The BASMI score is composed of 5 measures: tragus to wall distance, lumbar flexion, cervical rotation, lumbar side flexion, and intermalleolar distance. Each measure was scored 0-2 (0=normal mobility/mild disease involvement, 1=moderate disease involvement, 2=severe disease involvement) to give a final total score ranging from 0 to 10. The higher the BASMI score, the more severe was the subject's limitation of movement due to their AS.
| units on scale | Adalimumab |
|---|---|
| Week 12 | -0.4 (-0.79 to -0.02) |
| Week 24 | -0.5 (-0.90 to -0.17) |
| Week 48 | -0.6 (-1.07 to -0.23) |
| Week 72 | -0.5 (-0.95 to -0.06) |
| Week 96 | -0.6 (-1.03 to -0.13) |
| Week 120 | -0.7 (-1.09 to -0.22) |
| Final Visit | -0.6 (-1.00 to -0.21) |
Chest expansion is the difference in centimeters between full expiration and full inspiration, measured at the 4th inter-costal space. An increase in chest expansion represents improvement.
| cm | Adalimumab |
|---|---|
| Week 12 | 0.7 (0.30 to 1.03) |
| Week 24 | 0.4 (0.16 to 0.66) |
| Week 48 | 0.8 (0.40 to 1.17) |
| Week 72 | 1.0 (0.56 to 1.46) |
| Week 96 | 0.6 (0.19 to 1.11) |
| Week 120 | 1.1 (0.55 to 1.72) |
| Final Visit | 1.2 (0.54 to 1.80) |
Assessment of enthesitis was performed in the following 7 domains: 1) 1st costochondral joint left and right, 2) 7th costochondral joint left and right, 3) posterior superior iliac spine left and right, 4) anterior superior iliac spine left and right, 5) iliac crest left and right, 6) 5th lumbar spinous process and 7) proximal insertion of Achilles tendon left and right. Each domain was graded for the presence (1) and absence (0) of tenderness yielding total MASES ranging from 0 (no tenderness) to 13 (worst possible score; severe tenderness).
| units on a scale | Adalimumab |
|---|---|
| Week 12 | -1.0 (-1.71 to -0.39) |
| Week 24 | -1.1 (-1.76 to -0.53) |
| Week 48 | -1.3 (-1.90 to -0.74) |
| Week 72 | -1.1 (-1.72 to -0.48) |
| Week 96 | -1.4 (-1.98 to -0.85) |
| Week 120 | -1.4 (-1.96 to -0.77) |
| Final Visit | -1.4 (-1.96 to -0.77) |
Nocturnal pain assessed by subjects using a Visual Analog Scale (VAS) of 0 - 100 mm (0 = no pain and 100 = worst possible pain).
| mm on scale | Adalimumab |
|---|---|
| Week 12 | -30.0 (-39.71 to -20.29) |
| Week 24 | -31.7 (-41.92 to -21.54) |
| Week 48 | -35.8 (-45.04 to -26.61) |
| Week 72 | -34.6 (-43.45 to -25.77) |
| Week 96 | -33.4 (-43.14 to -23.69) |
| Week 120 | -35.0 (-44.10 to -25.85) |
| Final Visit | -35.3 (-44.52 to -26.07) |
The number of swollen joints among 22 anatomical joints for both the right and left side of the body were assessed by a joint evaluator where the presence of a swollen joint was scored as 1 and absence as 0. The total SJC was derived by the sum of the scores for a range of SJC from 0 (best possible score; no swollen joints) to 44 (worse possible score; all joints swollen).
| SJC | Adalimumab |
|---|---|
| Week 12 | -1.1 (-1.91 to -0.38) |
| Week 24 | -1.1 (-1.81 to -0.34) |
| Week 48 | -1.1 (-1.97 to -0.32) |
| Week 72 | -1.3 (-2.17 to -0.37) |
| Week 96 | -1.2 (-1.99 to -0.44) |
| Week 120 | -1.2 (-2.01 to -0.43) |
| Final Visit | -1.2 (-1.94 to -0.40) |
The number of tender or painful joints among 23 anatomical joints for both the right and left side of the body were assessed by a joint evaluator where the presence of a tender or painful joint was scored as 1 and absence as 0. The total TJC was derived by the sum of the scores for a range of TJC from 0 (best possible score; no tender or painful joints) to 46 (worst possible score; all joints tender or painful).
| TJC | Adalimumab |
|---|---|
| Week 12 | -1.5 (-3.86 to 0.94) |
| Week 24 | -1.4 (-3.66 to 0.87) |
| Week 48 | -1.3 (-3.60 to 0.96) |
| Week 72 | -1.6 (-4.00 to 0.88) |
| Week 96 | -1.6 (-3.63 to 0.46) |
| Week 120 | -1.6 (-3.69 to 0.56) |
| Final Visit | -1.6 (-3.69 to 0.56) |
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These are summarized in a physical component summary (PCS) and mental component summary (MCS) score. The score for a section is an average of the individual question scores, which are scaled 0-100 (0=lowest level of functioning; 100=highest level of functioning).
| units on scale | Adalimumab |
|---|---|
| PCS Week 12 | 9.6 (6.81 to 12.40) |
| PCS Week 24 | 10.6 (7.51 to 13.67) |
| PCS Week 48 | 11.4 (8.69 to 14.06) |
| PCS Week 72 | 11.3 (8.29 to 14.30) |
| PCS Week 96 | 12.3 (9.25 to 15.37) |
| PCS Week 120 | 12.1 (9.07 to 15.19) |
| PCS Final Visit | 12.6 (9.75 to 15.53) |
| MCS Week 12 | 7.0 (3.07 to 10.87) |
| MCS Week 24 | 7.0 (3.62 to 10.34) |
| MCS Week 48 | 6.1 (2.52 to 9.59) |
| MCS Week 72 | 6.7 (2.94 to 10.53) |
| MCS Week 96 | 5.8 (2.55 to 9.09) |
| MCS Week 120 | 6.1 (2.63 to 9.59) |
| MCS Final Visit | 5.9 (2.44 to 9.42) |
Collected over All adverse events reported from the time of first study drug administration until 70 days following discontinuation of study drug administration were collected.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab | — | 6/41 (14.6%) | 41/41 (100%) |
| Event | Adalimumab |
|---|---|
| CataractEye disorders | 2/41 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/41 |
| Intervertebral discitisInfections and infestations | 1/41 |
| OsteomyelitisInfections and infestations | 1/41 |
| PneumoniaInfections and infestations | 1/41 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/41 |
| PeriodontitisGastrointestinal disorders | 1/41 |
| Septic shockInfections and infestations | 1/41 |
| AdenomyosisReproductive system and breast disorders | 1/41 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/41 |
| Event | Adalimumab |
|---|---|
| NasopharyngitisInfections and infestations | 22/41 |
| Hepatic function abnormalHepatobiliary disorders | 9/41 |
| DiarrhoeaGastrointestinal disorders | 8/41 |
| Upper respiratory tract infectionInfections and infestations | 8/41 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 8/41 |
| Upper respiratory tract infectionInfections and infestations | 7/41 |
| Injection site erythemaGeneral disorders | 6/41 |
| Ankylosing spondylitisMusculoskeletal and connective tissue disorders | 6/41 |
| ContusionInjury, poisoning and procedural complications | 6/41 |
| HeadacheNervous system disorders | 5/41 |
| Age, Customized(subjects) | Adalimumab |
|---|---|
| <40 years | 25 |
| Between 40 and 65 years | 16 |
| >65 years | 0 |
| Age Continuous(years) | Adalimumab |
|---|---|
| Mean | 37.2 ± 12.17 |
| Sex: Female, Male(Participants) | Adalimumab |
|---|---|
| Female | 9 |
| Male | 32 |
| Region of Enrollment(subjects) | Adalimumab |
|---|---|
| Japan | 41 |
The record gives a start of Feb 2008, a primary completion of May 2009 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab